Radiosynthesis of 11C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The multistep preparation of (11)C-levetiracetam ((11)C-LEV) was carried out by a one-pot radiosynthesis with 8.3 ± 1.6% (n = 8) radiochemical yield in 50 ± 5.0 min. Briefly, the propionaldehyde was converted to propan-1-imine in situ as labeling precursor by incubation with ammonia. Without further separation, the imine was reacted with (11)C-HCN to form (11)C-aminonitrile. This crude was then reacted with 4-chlorobutyryl chloride and followed by hydrolysis to yield (11)C-LEV after purification by chiral high-performance liquid chromatography (HPLC). Both the radiochemical and enantiomeric purities of (11)C-LEV were >98%.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the first attempt to develop a SV2A-PET radioligand was [ 11 C]levetiracetam”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [108]
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Sanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G.-Q., Palop, J. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121081109 · Cited by 638
Barton, D. H. R., Crich, D., & Motherwell, W. B. (1985) · Tetrahedron · doi:10.1016/s0040-4020(01)97173-x · Cited by 537
Levetiracetam: a review of its use in epilepsy.
Lyseng-Williamson, K. A. (2011) · PubMed · doi:10.2165/11204490-000000000-00000 · Cited by 194
The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development
Wong, D. F., Tauscher, J., & Gründer, G. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.166 · Cited by 166
Neves, A. A., & Brindle, K. M. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114264 · Cited by 158
Surges, R., Volynski, K. E., & Walker, M. C. (2008) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285608094212 · Cited by 129
Synaptic vesicle protein 2A: basic facts and role in synaptic function
Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124
11CO2 fixation: a renaissance in PET radiochemistry
Rotstein, B. H., Liang, S. H., Holland, J. P., Collier, T. L., Hooker, J. M., Wilson, A. A., & Vasdev, N. (2013) · Chemical Communications · doi:10.1039/c3cc42236d · Cited by 98
Evaluation of18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain
Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136143 · Cited by 85
Research works printed but not linked: 1
- Sanchez P. E., 2012, Proc. Natl. Acad. Sci. U.S.A., 109, E2895
Cited by
Nabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296
“1) is feasible (10), it is likely that its affinity is too low and its brain penetration not sufficiently fast to perform well as a PET tracer.”
BackgroundFinnema, S. J., Nabulsi, N. B., Mercier, J., Lin, S.-F., Chen, M.-K., Matuskey, D., Gallezot, J.-D., Henry, S., Hannestad, J., Huang, Y., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17724947 · Cited by 218
Rafiee, M., Konz, Z. M., Graaf, M. D., Koolman, H. F., & Stahl, S. S. (2018) · ACS Catalysis · doi:10.1021/acscatal.8b01640 · Cited by 186
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
Imaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77
Yadav, K. S., Soni, G., Choudhary, D. K., Khanduri, A., Bhandari, A., & Joshi, G. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100162 · Cited by 77
[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A
Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.03.004 · Cited by 71
“Recently two radioligands for the study of SV2A were presented, [F]UCB-H and [C]levetiracetam [13–15].”
MethodImaging Synaptic Density: The Next Holy Grail of Neuroscience?
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67
Recent progress in [11C]carbon dioxide ([11C]CO2) and [11C]carbon monoxide ([11C]CO) chemistry
Taddei, C., & Gee, A. D. (2017) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3596 · Cited by 65
Synaptic vesicle protein 2: A multi-faceted regulator of secretion
Ciruelas, K., Marcotulli, D., & Bajjalieh, S. M. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.02.003 · Cited by 55
Amino sulfonic acids, peptidosulfonamides and other related compounds
Grygorenko, O. O., Biitseva, A. V., & Zhersh, S. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.01.033 · Cited by 62
PET Imaging for Early Detection of Alzheimer’s Disease
Bao, W., Jia, H., Finnema, S. J., Cai, Z., Carson, R. E., & Huang, Y. H. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.03.001 · Cited by 59
Mercier, J., Provins, L., & Valade, A. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.11.003 · Cited by 59
Cai, Z., Li, S., Zhang, W., Pracitto, R., Wu, X., Baum, E., Finnema, S. J., Holden, D., Toyonaga, T., Lin, S.-F., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00618 · Cited by 54
Bretin, F., Bahri, M. A., Bernard, C., Warnock, G., Aerts, J. J., Mestdagh, N., Buchanan, T. J., Otoul, C., Koestler, F., Miévis, F., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0820-6 · Cited by 56
He, Y., Zheng, Z. G., Liu, Y., Qiao, J., Zhang, X., & Fan, X. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b00226 · Cited by 55
Validation and noninvasive kinetic modeling of [ 11 C]UCB-J PET imaging in mice
Bertoglio, D., Verhaeghe, J., Miranda, A., Kertesz, I., Cybulska, K., Korat, Š., Wyffels, L., Stroobants, S., Mrzljak, L., Dominguez, C., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19864081 · Cited by 54
Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy
Bagnato, F. R., Gauthier, S. A., Laule, C., Moore, G. R. W., Bove, R. M., Cai, Z., Cohen‐Adad, J., Harrison, D. M., Klawiter, E. C., Morrow, S. A., et al. (2020) · Journal of Neuroimaging · doi:10.1111/jon.12700 · Cited by 43
SV2A PET imaging in human neurodegenerative diseases
Bavarsad, M. S., & Grinberg, L. T. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380561 · Cited by 39
The Rise of Synaptic Density PET Imaging
Becker, G., Dammicco, S., Bahri, M. A., & Salmon, E. (2020) · Molecules · doi:10.3390/molecules25102303 · Cited by 31
Synaptic changes in psychiatric and neurological disorders: State-of-the art of in vivo imaging
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01943-x · Cited by 34
PET Imaging in Animal Models of Alzheimer’s Disease
Chen, B., Marquez-Nostra, B. V., Belitzky, E., Toyonaga, T., Tong, J., Huang, Y. H., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.872509 · Cited by 32
Small Molecule PET Tracers for Transporter Imaging
Kilbourn, M. R. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.05.005 · Cited by 29
[11C]HCN Radiochemistry: Recent Progress and Future Perspectives
Xu, Y., & Qü, W. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100651 · Cited by 28
Harikandei, K. B., Salehi, P., Ebrahimi, S. N., Bararjanian, M., Kaiser, M., Khavasi, H. R., & Al‐Harrasi, A. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103116 · Cited by 25
Imaging Synaptic Density: A Different Look at Neurologic Diseases
Rabiner, E. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198317 · Cited by 20
Rashed, H. M., Shamma, R. N., & El-Sabagh, H. A. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.05.019 · Cited by 21
Radiolabeling with [11C]HCN for Positron emission tomography
Zhou, Y., Makaravage, K. J., & Brugarolas, P. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.09.002 · Cited by 19
PET Imaging of Synaptic Vesicle Protein 2A
Finnema, S. J., Li, S., Cai, Z., Naganawa, M., Chen, M.-K., Matuskey, D., Nabulsi, N., Esterlis, I., Holmes, S. E., Radhakrishnan, R., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_29 · Cited by 19
Shao, X., Xing, J., Brooks, A. F., Fink, D., Zhang, H., Piert, M., & Scott, P. J. H. (2016) · Synlett · doi:10.1055/s-0036-1588638 · Cited by 18
Controlled-potential electrolysis for evaluating molecular electrocatalysts
Katipamula, S., White, N. M., & Waldie, K. M. (2023) · Chem Catalysis · doi:10.1016/j.checat.2023.100561 · Cited by 14
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Kong, Y., Zhang, S., Huang, L., Zhang, C., Xie, F., Zhang, Z., Huang, Q., Jiang, D., Li, J., Zhou, W., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.731114 · Cited by 13
Thompson, S., Kealey, S., Sephton, S. M., & Aigbirhio, F. I. (2020) · Wiley eBooks · doi:10.1002/9781119500575.ch7 · Cited by 13
Navacerrada, M. E. S., Becker, G., Bahri, M. A., Seret, A., Mestdagh, N., Mercier, J., Miévis, F., Giacomelli, F., Lemaire, C. F., Salmon, É., et al. (2019) · Molecules · doi:10.3390/molecules24091705 · Cited by 13
Application of chiral chromatography in radiopharmaceutical fields: A review
Moein, M. M., & Tran, T. A. (2020) · Journal of Chromatography A · doi:10.1016/j.chroma.2020.461611 · Cited by 12
Carbon isotopic labelling of carboxylic acids enabled by organic photoredox-catalysed cyanation
Zhu, Z., Wu, X., Bida, G. T., Deng, H., Ma, X., Qian, S., Wu, Z., Li, Z., & Nicewicz, D. A. (2024) · Nature Synthesis · doi:10.1038/s44160-024-00656-9 · Cited by 11
Total synthesis of levetiracetam
Narczyk, A., Mrozowicz, M., & Stecko, S. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00111e · Cited by 11
Green Oxidative Catalytic Processes for the Preparation of APIs and Precursors
García‐Fernández, P. D., Coto‐Cid, J. M., & de Gonzalo, G. (2023) · Catalysts · doi:10.3390/catal13030638 · Cited by 10
McErlain, H., McLean, E., Morgan, T. E. F., Burianova, V. K., Tavares, A., & Sutherland, A. J. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c01895 · Cited by 9
A Short Review on the Synthetic Routes for the Antiepileptic Drug (S)-Levetiracetam
Paul, S., & Bhattacharya, A. K. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.4c00002 · Cited by 8
Progress and Challenges in the Development of PET Ligands to Aid CNS Drug Discovery
Mercier, J., Provins, L., & Hannestad, J. O. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12437-0 · Cited by 8
Molins, M., Hauwelle, A., Fogel, L. E., Lemesre, Q., Loreau, O., Taran, F., Caillé, F., & Audisio, D. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c11876 · Cited by 6
Widespread synaptic density loss in schizophrenia follows molecular and network architecture
Chopra, S., Worhunsky, P. D., Naganawa, M., Zhang, X.-H., Segal, A., Labache, L., Orchard, E. R., Cropley, V., Wood, S. J., Angarita, G. A., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03717-x · Cited by 5
Lu, X., Ji, B., Huang, G., & Ding, H. Y. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.04.013 · Cited by 5
Jiang, Z., Cheng, X., Chen, H., Zheng, W., Sun, Y., Yu, Z., Yang, T., Zhang, L., Fan, D., Yang, Z., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00062 · Cited by 5
Advances in the Synthesis of Levetiracetam: Classical Approaches and Patented Innovations
Sivaprakash, M., Tejaswini, K. B., Pulukuri, K. K., Gopinath, P., & Balaraman, E. (2026) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.70358 · Cited by 4
Li, J., Zou, R., Varrone, A., Nag, S., Halldin, C., & Ågren, H. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00029 · Cited by 4
Diagnostic and theranostic intranasal nanointerventions for brain diseases
Upadhaya, P. G., Pulakkat, S., & Patravale, V. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822522-6.00013-8 · Cited by 4
Dose reduction for synaptic density PET imaging in Parkinson’s disease
Li, A., Naganawa, M., Honhar, P., Fontaine, K. M., Gravel, P., Matuskey, D., Carson, R. E., & Tang, J. (2026) · NeuroImage · doi:10.1016/j.neuroimage.2026.121853 · Cited by 2
Su, S., Zhu, M., Zhang, D., & Yuan, D. (2019) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc201812019 · Cited by 2
Sepsis and Systemic Inflammatory Syndromes
Romijnders, M., Snoek, B., van Oss, L., Pickkers, P., & Abdo, W. F. (2026) · Critical Care Clinics · doi:10.1016/j.ccc.2026.05.012 · Cited by 1
Synaptic PET Imaging in Neurodegeneration
Chen, M., Matuskey, D., Finnema, S. J., & Carson, R. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_10 · Cited by 1
New PET radiopharmaceuticals for imaging CNS diseases
Brumberg, J., & Varrone, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00002-8
Application of SV2A PET in neurodegenerative disorders
Chen, D., & JIANG, H. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0086
Fluid and Imaging Markers of Synaptic Injury
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_4
The synthesis and development of radionuclide based tracers for the imaging of diseases
Burianova, V. (2025) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.85384
Metadata
- Authors
- Cai, H., Mangner, T. J., Muzik, O., Wang, M.-W., Chugani, D. C., & Chugani, H. T.
- Affiliations
- Detroit Medical Center (US)
- Corresponding author
- Cai, Hancheng
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-08-27
- Volume
- 5
- Issue
- 10
- Pages
- 1152-1155
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4190623
- OpenAlex
- W2322216374
- Cited by
- 58
- References
- 27
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 8 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 7 · 2016: 4 · 2015: 1
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wayne State University
- Children's Hospital of Michigan
- Institute of Chemistry, Chinese Academy of Sciences
- Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Chemical Reactions and Isotopes
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- radiotracer synthesis, one-pot synthesis, SV2A, positron emission tomography, carbon-11, aminonitriles, enantiomeric purity, chiral HPLC, propionaldehyde
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.